As an important part of the pharmaceutical industry, the pharmaceutical manufacturing industry is always at the battlefield of the international public health and health industry. At the same time, as a basic and stra...As an important part of the pharmaceutical industry, the pharmaceutical manufacturing industry is always at the battlefield of the international public health and health industry. At the same time, as a basic and strategic sub-industry in China's manufacturing industry, the medical manufacturing industry closely related to people’s livelihood which is not only related to social Responsibility but also plays a key role in China's economy today. For the Chinese people, the new medical reforms and the irreversible aging of the population have increased the nation’s total expenditure on health care. From January to October 2017, the pharmaceutical industry’s main business income was RMB 2,410.29 billion, a year-on-year increase of 13.10%. This is a 4.50 percentage point higher than the 10.30% growth rate in 2016. However, even if the circumstance of this industry is getting better, high growth also has a drag on the national health insurance system and the standard of living of the people. This article chooses to analyze the financial and operating-level factors of China's pharmaceutical manufacturing listed companies such as Inventory turnover rate and operating rate. Study the impact on the performance of China's pharmaceutical manufacturing listed companies. The results of the study will fill gaps in the research of this industry and help pharmaceutical manufacturing listed companies choose the right capital size, liabilities, and expansion strategies, and more effectively absorb the current development dividends of China’s “four new economy”, and use them rationally and effectively. Markets and complex and limited capital and resources of enterprises, as China's industry benchmarks continue to guide the rapid growth of the market. on the other hand, to help investor the empirical point of view better choice of investment targets. This paper uses data from 2007-2016 for randomly selecting 19 companies from 118 medical manufacturing listed companies classified by China Securities Regulatory Commission. After dealing with panel data, multiple inspections are performed on panel data. To avoid the deviation from the actual level of the regression results, the panel-corrected standard deviation model was used to derive the relationship between the operating-level factors of pharmaceutical manufacturing listed companies and their performance. The results of the study indicate that there is a positive correlation between Inventory turnover rate, operating rate and performance, which fills the domestic empirical research on this issue. This area of industry company performance is blank.展开更多
文摘As an important part of the pharmaceutical industry, the pharmaceutical manufacturing industry is always at the battlefield of the international public health and health industry. At the same time, as a basic and strategic sub-industry in China's manufacturing industry, the medical manufacturing industry closely related to people’s livelihood which is not only related to social Responsibility but also plays a key role in China's economy today. For the Chinese people, the new medical reforms and the irreversible aging of the population have increased the nation’s total expenditure on health care. From January to October 2017, the pharmaceutical industry’s main business income was RMB 2,410.29 billion, a year-on-year increase of 13.10%. This is a 4.50 percentage point higher than the 10.30% growth rate in 2016. However, even if the circumstance of this industry is getting better, high growth also has a drag on the national health insurance system and the standard of living of the people. This article chooses to analyze the financial and operating-level factors of China's pharmaceutical manufacturing listed companies such as Inventory turnover rate and operating rate. Study the impact on the performance of China's pharmaceutical manufacturing listed companies. The results of the study will fill gaps in the research of this industry and help pharmaceutical manufacturing listed companies choose the right capital size, liabilities, and expansion strategies, and more effectively absorb the current development dividends of China’s “four new economy”, and use them rationally and effectively. Markets and complex and limited capital and resources of enterprises, as China's industry benchmarks continue to guide the rapid growth of the market. on the other hand, to help investor the empirical point of view better choice of investment targets. This paper uses data from 2007-2016 for randomly selecting 19 companies from 118 medical manufacturing listed companies classified by China Securities Regulatory Commission. After dealing with panel data, multiple inspections are performed on panel data. To avoid the deviation from the actual level of the regression results, the panel-corrected standard deviation model was used to derive the relationship between the operating-level factors of pharmaceutical manufacturing listed companies and their performance. The results of the study indicate that there is a positive correlation between Inventory turnover rate, operating rate and performance, which fills the domestic empirical research on this issue. This area of industry company performance is blank.
